The effect of age on clinical pharmacokinetics of piracetam.
In this study the pharmacokinetics of 2-oxopyrrolidine-1-acetamide (piracetam, Nootrop), were studied in 10 geriatric patients with multiple diseases aged between 69 and 87 years. After intravenous administration of 6 g piracetam, the concentration of the drug in plasma was measured after 5, 10, 15 and 30 min as well as after 1, 2, 4, 6, 8, 10, 12 and 24 h. An analysis of laboratory diagnostic findings was carried out in parallel. The kinetic parameters were correlated with the laboratory diagnostic data and discussed together with the currently available results in the literature. The finding which seems to be of particular significance is that multimorbidity is a more important factor influencing the pharmacokinetics than age.
D000328:Adult; D000368:Aged; D000375:Aging; D001798:Blood Proteins / Q000378:metabolism; D001835:Body Weight; D004912:Erythrocytes / Q000378:metabolism; D005260:Female; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008297:Male; D008954:Models, Biological; D009961:Orosomucoid / Q000378:metabolism; D010889:Piracetam / Q000378:metabolism*; D011485:Protein Binding; D011760:Pyrrolidinones / Q000378:metabolism*; D014508:Urea / Q000097:blood
D001798:Blood Proteins; D009961:Orosomucoid; D011760:Pyrrolidinones; D014508:Urea; D010889:Piracetam